Application of microfluidic technologies on COVID-19 diagnosis and drug discovery DOI Creative Commons
Zhun Lin, Zhengyu Zou, Zhe Pu

и другие.

Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 13(7), С. 2877 - 2896

Опубликована: Фев. 24, 2023

The ongoing coronavirus disease 2019 (COVID-19) pandemic has boosted the development of antiviral research. Microfluidic technologies offer powerful platforms for diagnosis and drug discovery severe acute respiratory syndrome 2 (SARS-CoV-2) discovery. In this review, we introduce structure SARS-CoV-2 basic knowledge microfluidic design. We discuss application devices in based on detecting viral nucleic acid, antibodies, antigens. highlight contribution lab-on-a-chip to manufacturing point-of-care equipment accurate, sensitive, low-cost, user-friendly virus-detection devices. then investigate efforts organ-on-a-chip lipid nanoparticles (LNPs) synthesizing chips screening mRNA vaccine preparation. contribute research provide tools future outbreaks.

Язык: Английский

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment DOI Open Access
Cathrine Lund Lorentzen, John B.A.G. Haanen, Özcan Met

и другие.

The Lancet Oncology, Год журнала: 2022, Номер 23(10), С. e450 - e458

Опубликована: Сен. 26, 2022

Язык: Английский

Процитировано

338

mRNA-based cancer therapeutics DOI
Chuang LIU,

Qiangqiang Shi,

Xiangang Huang

и другие.

Nature reviews. Cancer, Год журнала: 2023, Номер 23(8), С. 526 - 543

Опубликована: Июнь 13, 2023

Язык: Английский

Процитировано

233

Therapeutic cancer vaccines: advancements, challenges and prospects DOI Creative Commons
Ting Fan, Mingna Zhang, Jingxian Yang

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)

Опубликована: Дек. 13, 2023

With the development and regulatory approval of immune checkpoint inhibitors adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over past decades. Recently, therapeutic vaccines have shown promise by eliciting de novo T responses targeting tumor antigens, including tumor-associated antigens tumor-specific antigens. The objective was to amplify diversify intrinsic repertoire cells. However, complete realization these capabilities remains an ongoing pursuit. Therefore, we provide overview current landscape in this review. range antigen selection, delivery systems strategic nuances underlying effective presentation pioneered vaccine design. Furthermore, review addresses status clinical trials discusses their strategies, focusing on immunogenicity anti-tumor efficacy assessment. attempts toward developing not yielded breakthrough outcomes due significant challenges, microenvironment suppression, optimal candidate identification, response evaluation, manufacturing acceleration. field is poised overcome hurdles improve patient future acknowledging complexities persistently striving surmount inherent constraints.

Язык: Английский

Процитировано

221

Precision treatment in advanced hepatocellular carcinoma DOI Creative Commons
Xupeng Yang, Chen Yang, Shu Zhang

и другие.

Cancer Cell, Год журнала: 2024, Номер 42(2), С. 180 - 197

Опубликована: Фев. 1, 2024

The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, newly developed strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision represents a paradigm shift cancer recent years. This approach utilizes unique molecular characteristics individual patient personalize modalities, aiming maximize efficacy while minimizing side effects. Although precision shown multiple types, its application remains infancy. In this review, we discuss key aspects HCC, including biomarkers, classifications, heterogeneity tumor microenvironment. We also propose future directions, ranging from revolutionizing current methodologies personalizing therapy through functional assays, which will accelerate next phase advancements area.

Язык: Английский

Процитировано

139

Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies DOI Creative Commons
Hongjian Li, Kun Peng, Kai Yang

и другие.

Theranostics, Год журнала: 2022, Номер 12(14), С. 6422 - 6436

Опубликована: Янв. 1, 2022

Rationale: Messenger RNA (mRNA) vaccine outperforms other kinds of cancer immunotherapy due to its high response rates, easy preparation, and wide applicability, which is considered as one the most promising forms next-generation therapies.However, inherent instability insufficient protein expression duration mRNA limit efficacy widespread application vaccine.Methods: Here, we first tested possibility a novel circular (circRNA) platform for compare with linear RNA.Then, developed lipid nanoparticle (LNP) system circRNA delivery in vitro vivo.Next, innate adaptive immune circRNA-LNP complex was evaluated vivo.The anti-tumor further confirmed three tumor models.Finally, combination therapy adoptive cell transfer investigated late-stage model. Results:We successfully increased stability by circularizing molecules form highly stable exhibited durable ability.By encapsulating antigen-coding LNP enabling vivo expression, established platform, capable triggering robust activation showed superior multiple mouse models.Conclusions: Overall, our provides prospect development vaccines range hard-to-treat malignancies.

Язык: Английский

Процитировано

125

Circular RNA vaccine in disease prevention and treatment DOI Creative Commons
Dun Niu, Yaran Wu, Jiqin Lian

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)

Опубликована: Сен. 11, 2023

Abstract CircRNAs are a class of single-stranded RNAs with covalently linked head-to-tail topology. In the decades since its initial discovery, their biogenesis, regulation, and function have rapidly disclosed, permitting better understanding adoption them as new tools for medical applications. With development biotechnology molecular medicine, artificial circRNAs been engineered novel vaccines disease treatment prevention. Unlike linear mRNA vaccine which applications were limited by instability, inefficiency, innate immunogenicity, circRNA incorporate internal ribosome entry sites (IRESs) open reading frame (ORF) provides an improved approach to RNA-based vaccination safety, stability, simplicity manufacture, scalability. However, at early stage, optimization, delivery require further evaluation. this review, we comprehensively describe vaccine, including history superiority. We also summarize discuss current methodological research preparation, design, synthesis, purification. Finally, highlight options potential in diseases Considering unique high low protein/peptide-coding capacity special closed-loop construction, circRNA-based therapeutic platforms may superior application prospects broad range diseases.

Язык: Английский

Процитировано

106

mRNA vaccines for cancer immunotherapy DOI Creative Commons
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Дек. 14, 2022

Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against because of their high potency, specificity, versatility, rapid large-scale development capability, low-cost manufacturing potential, safety. Recent technological advances vaccine design delivery have accelerated vaccines’ clinical application. In this review, we present various platforms with focus on nucleic acid vaccines. We discuss rational optimization strategies for development. highlight the available lipid nanoparticles (LNPs) based systems. Finally, limitations future challenges.

Язык: Английский

Процитировано

97

mRNA-based therapeutics: looking beyond COVID-19 vaccines DOI
Hamideh Parhiz, Elena N. Atochina‐Vasserman, Drew Weissman

и другие.

The Lancet, Год журнала: 2024, Номер 403(10432), С. 1192 - 1204

Опубликована: Март 1, 2024

Язык: Английский

Процитировано

82

Recent Advances in Lipid Nanoparticles for Delivery of mRNA DOI Creative Commons
Lei Yang, Liming Gong, Ping Wang

и другие.

Pharmaceutics, Год журнала: 2022, Номер 14(12), С. 2682 - 2682

Опубликована: Дек. 1, 2022

Messenger RNA (mRNA), which is composed of ribonucleotides that carry genetic information and direct protein synthesis, transcribed from a strand DNA as template. On this basis, mRNA technology can take advantage the body's own translation system to express proteins with multiple functions for treatment various diseases. Due advancement synthesis purification, modification sequence optimization technologies, emerging lipid nanomaterials other delivery systems, therapeutic regimens are becoming clinically feasible exhibit significant reliability in stability, efficiency, controlled immunogenicity. Lipid nanoparticles (LNPs), currently leading non-viral vehicles, have made many exciting advances clinical part COVID-19 vaccines therefore potential accelerate gene drugs. Additionally, due their small size, biocompatibility, biodegradability, LNPs effectively deliver nucleic acids into cells, particularly important current regimens. Therefore, cutting-edge LNP@mRNA hold great promise cancer vaccines, infectious disease prevention, replacement therapy, editing, rare treatment. To shed more lights on LNP@mRNA, paper mainly discusses rational choosing vectors mRNA, general rules LNP preparation, parameters affecting efficiency finally summarizes research status well challenges. The latest progress diseases such oncological, cardiovascular, also given. Finally, future applications perspectives generally introduced.

Язык: Английский

Процитировано

76

mRNA vaccine in cancer therapy: Current advance and future outlook DOI Creative Commons

Youhuai Li,

Mina Wang, Xueqiang Peng

и другие.

Clinical and Translational Medicine, Год журнала: 2023, Номер 13(8)

Опубликована: Авг. 1, 2023

Abstract Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of that have shown great promise in the immunotherapy wide variety infectious diseases and cancer. In past 2 years, SARS‐CoV‐2 mRNA contributed tremendously against SARS‐CoV2, which has prompted arrival vaccine research boom, especially cancer vaccines. Compared with conventional vaccines, significant advantages, including efficient production protective immune responses, low side effects lower cost acquisition. this review, we elaborated on development as well potential biological mechanisms latest progress various tumour treatments, discussed challenges future directions for field.

Язык: Английский

Процитировано

75